Overview
Welcome to Immunicum's Investor Relations pages! Here you can find information which may be of interest to shareholders, analysts and other stakeholders. If you need more information or have any questions, please contact Alex Karlsson-Parra, INTERIM CEO.
Phone: +46(0)8 732 8400
Email: ir@immunicum.com
CEO statement, Year-end report 2019
“2019 was an important year for Immunicum. The results from the MERECA and GIST studies show clear and promising clinical results for ilixadencel in combination with tyrosine kinase inhibitors while maintaining ilixadencel’s favorable safety and tolerability profile“. – Alex Karlsson-Parra, interim CEO
To read the full report, please click here
Investor Downloads
